Skip to main content
Top
Published in: Clinical Rheumatology 10/2018

01-10-2018 | Original Article

Clinical outcomes and feasibility of the multidisciplinary management of patients with psoriatic arthritis: two-year clinical experience of a dermo-rheumatologic clinic

Authors: Michele Maria Luchetti, Devis Benfaremo, Anna Campanati, Elisa Molinelli, Monia Ciferri, Serena Cataldi, William Capeci, Marco Di Carlo, Anna Maria Offidani, Fausto Salaffi, Armando Gabrielli

Published in: Clinical Rheumatology | Issue 10/2018

Login to get access

Abstract

Psoriatic arthritis (PsA) is a chronic inflammatory autoimmune arthritis, occurring in patients with psoriasis (Pso), that may affect the whole musculoskeletal system but also nails, eye, and gastrointestinal tract. Dermatologists and rheumatologists usually manage Pso and PsA separately, but early diagnosis and integrated management could achieve better outcomes of both skin and musculoskeletal manifestations, thus improving the health-related quality of life (HRQoL) of patients. In this work, we have described a model of integrated dermo-rheumatologic approach for the early diagnosis of PsA and to present the outcomes of the multidisciplinary management of PsA patients after 48 weeks of follow-up. Pso patients complaining musculoskeletal symptoms were enrolled in a DErmo-Rheumatologic Clinic (DERC) in order to screen, classify, and treat patients with PsA, employing an operative working procedure and a specific flowchart. The integrated dermatologic and rheumatologic management of PsA patients allowed a prompt establishment of the diagnosis and the best therapeutic approach in these patients, with a significant improvement of skin and articular diseases and, eventually, a consistent amelioration of HRQoL. Dermatologists and rheumatologists usually manage the “psoriatic disease” in separated outpatient clinics. In our study, we have demonstrated that a combined DERC, by means of a tight cooperation between the dermatologist and the rheumatologist, which use a specific working procedure and treatment flowchart, may achieve the optimal clinical management of these patients, with a consistent clinical remission of the disease and a significant amelioration of the HRQoL.
Appendix
Available only for authorised users
Literature
4.
go back to reference Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowych WP, Mielants H, Sorensen IJ, Ozgocmen S, Roussou E, Valle-Onate R, Weber U, Wei J, Sieper J (2009) The development of assessment of SpondyloArthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68:777–783. https://doi.org/10.1136/ard.2009.108233 CrossRefPubMed Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowych WP, Mielants H, Sorensen IJ, Ozgocmen S, Roussou E, Valle-Onate R, Weber U, Wei J, Sieper J (2009) The development of assessment of SpondyloArthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68:777–783. https://​doi.​org/​10.​1136/​ard.​2009.​108233 CrossRefPubMed
5.
go back to reference Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT, Dougados M, Huang F, Gu J, Kirazli Y, van den Bosch F, Olivieri I, Roussou E, Scarpato S, Sorensen IJ, Valle-Onate R, Weber U, Wei J, Sieper J (2010) The assessment of SpondyloArthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70:25–31. https://doi.org/10.1136/ard.2010.133645 CrossRefPubMed Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT, Dougados M, Huang F, Gu J, Kirazli Y, van den Bosch F, Olivieri I, Roussou E, Scarpato S, Sorensen IJ, Valle-Onate R, Weber U, Wei J, Sieper J (2010) The assessment of SpondyloArthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70:25–31. https://​doi.​org/​10.​1136/​ard.​2010.​133645 CrossRefPubMed
9.
go back to reference Gratacos-Masmitja J, Luelmo-Aguilar J, Zarco-Montejo P, Botella-Estrada R, Carrizosa-Esquivel AM, Garcia-Vivar ML, Perez-Barrio S, Roman-Ivorra JA, Ruiz-Montesino MD, Lopez-Estebaranz JL (2016) Points to consider in the Foundation of Multidisciplinary Units for psoriatic arthritis: a Delphi study and a systematic review of the literature. Adv Ther 33:2150–2159. https://doi.org/10.1007/s12325-016-0429-z CrossRefPubMed Gratacos-Masmitja J, Luelmo-Aguilar J, Zarco-Montejo P, Botella-Estrada R, Carrizosa-Esquivel AM, Garcia-Vivar ML, Perez-Barrio S, Roman-Ivorra JA, Ruiz-Montesino MD, Lopez-Estebaranz JL (2016) Points to consider in the Foundation of Multidisciplinary Units for psoriatic arthritis: a Delphi study and a systematic review of the literature. Adv Ther 33:2150–2159. https://​doi.​org/​10.​1007/​s12325-016-0429-z CrossRefPubMed
11.
go back to reference Salaffi F, Di Carlo M, Luchetti MM et al (2018) A validation study of the simple psoriatic arthritis screening (SiPAS) questionnaire to screen psoriasis patients for psoriatic arthritis. Clin Exp Rheumatol 36:127–135PubMed Salaffi F, Di Carlo M, Luchetti MM et al (2018) A validation study of the simple psoriatic arthritis screening (SiPAS) questionnaire to screen psoriasis patients for psoriatic arthritis. Clin Exp Rheumatol 36:127–135PubMed
12.
go back to reference Gisondi P, Altomare G, Ayala F, Bardazzi F, Bianchi L, Chiricozzi A, Costanzo A, Conti A, Dapavo P, de Simone C, Foti C, Naldi L, Offidani A, Parodi A, Piaserico S, Prignano F, Rongioletti F, Stingeni L, Talamonti M, Girolomoni G (2017) Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 31:774–790. https://doi.org/10.1111/jdv.14114 CrossRefPubMed Gisondi P, Altomare G, Ayala F, Bardazzi F, Bianchi L, Chiricozzi A, Costanzo A, Conti A, Dapavo P, de Simone C, Foti C, Naldi L, Offidani A, Parodi A, Piaserico S, Prignano F, Rongioletti F, Stingeni L, Talamonti M, Girolomoni G (2017) Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 31:774–790. https://​doi.​org/​10.​1111/​jdv.​14114 CrossRefPubMed
21.
go back to reference Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, Papp K, Zrubek J, Mudivarthy S, Mack M, Visvanathan S, Beutler A (2009) Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 60:976–986. https://doi.org/10.1002/art.24403 CrossRefPubMed Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, Papp K, Zrubek J, Mudivarthy S, Mack M, Visvanathan S, Beutler A (2009) Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 60:976–986. https://​doi.​org/​10.​1002/​art.​24403 CrossRefPubMed
24.
25.
go back to reference Mease P, van der Heijde D, Ritchlin C, Okada M, Cuchacovich RS, Shuler CL, Lin CY, Braun DK, Lee CH, Gladman DD, SPIRIT-P1 Study Group (2016) Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis 76:79–87. https://doi.org/10.1136/annrheumdis-2016-209709 CrossRefPubMedPubMedCentral Mease P, van der Heijde D, Ritchlin C, Okada M, Cuchacovich RS, Shuler CL, Lin CY, Braun DK, Lee CH, Gladman DD, SPIRIT-P1 Study Group (2016) Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis 76:79–87. https://​doi.​org/​10.​1136/​annrheumdis-2016-209709 CrossRefPubMedPubMedCentral
30.
33.
go back to reference Foulkes A, Chinoy H, Warren RB (2012) High degree of patient satisfaction and exceptional feedback in a specialist combined dermatology and rheumatology clinic. Br J Dermatol 167:38 Foulkes A, Chinoy H, Warren RB (2012) High degree of patient satisfaction and exceptional feedback in a specialist combined dermatology and rheumatology clinic. Br J Dermatol 167:38
34.
go back to reference Di Carlo M, Luchetti M, Benfaremo D et al (2017) The DETection of arthritis in inflammatory boweL diseases (DETAIL) questionnaire: development and preliminary testing of a new tool to screen patients with inflammatory bowel disease for the presence of spondyloarthritis. Clin Rheumatol 37:1037–1044. https://doi.org/10.1007/s10067-017-3937-6 CrossRefPubMed Di Carlo M, Luchetti M, Benfaremo D et al (2017) The DETection of arthritis in inflammatory boweL diseases (DETAIL) questionnaire: development and preliminary testing of a new tool to screen patients with inflammatory bowel disease for the presence of spondyloarthritis. Clin Rheumatol 37:1037–1044. https://​doi.​org/​10.​1007/​s10067-017-3937-6 CrossRefPubMed
41.
go back to reference Coates L, Tillett W, Chandler D, Helliwell PS, Korendowych E, Kyle S, McInnes I, Oliver S, Ormerod A, Smith C, Symmons D, Waldron N, McHugh N, BSR Clinical Affairs Committee & Standards, Audit and Guidelines Working Group and the BHPR (2013) The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. Rheumatology 52:1754–1757. https://doi.org/10.1093/rheumatology/ket187 CrossRefPubMed Coates L, Tillett W, Chandler D, Helliwell PS, Korendowych E, Kyle S, McInnes I, Oliver S, Ormerod A, Smith C, Symmons D, Waldron N, McHugh N, BSR Clinical Affairs Committee & Standards, Audit and Guidelines Working Group and the BHPR (2013) The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. Rheumatology 52:1754–1757. https://​doi.​org/​10.​1093/​rheumatology/​ket187 CrossRefPubMed
Metadata
Title
Clinical outcomes and feasibility of the multidisciplinary management of patients with psoriatic arthritis: two-year clinical experience of a dermo-rheumatologic clinic
Authors
Michele Maria Luchetti
Devis Benfaremo
Anna Campanati
Elisa Molinelli
Monia Ciferri
Serena Cataldi
William Capeci
Marco Di Carlo
Anna Maria Offidani
Fausto Salaffi
Armando Gabrielli
Publication date
01-10-2018
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 10/2018
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-018-4238-4

Other articles of this Issue 10/2018

Clinical Rheumatology 10/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.